Structure-Function Relationships of Multidrug Resistance P-Glycoprotein

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2523-2533

  Pajeva, Ilza K ^a,b   Globisch, Christoph ^b   Wiese, Michael ^b  

^a CENTRE OF BIOMEDICAL ENGINEERING   (Bulgaria)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; GLYCOPROTEIN P; HOE 33342; MSBA LIPID TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; ESCHERICHIA COLI; EXPERIMENTAL MODEL; HUMAN; LIPID TRANSPORT; NONHUMAN; PHARMACOPHORE; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; TRANSMEMBRANE DOMAIN 11; TRANSMEMBRANE DOMAIN 12; TRANSMEMBRANE DOMAIN 5; TRANSMEMBRANE DOMAIN 6; VIBRIO CHOLERAE;

AMINO ACID SEQUENCE; BENZIMIDAZOLES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, MULTIPLE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEIN;

EID: 2342533129     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031009p     Document Type: Article

References (34)

1. Stein, W. D. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol. Rev. 1997, 77, 545-590.
2. van de Waterbeemd, H. Role of human CYP3A and P-glycoprotein on the absorption of drugs. Eur. J. Pharm. Sci. 2000, 12, 1.
3. Lin, J. H.; Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 2003, 42, 59-98.
4. Rosenberg, M. F.; Kamis, A. B.; Callaghan, R.; Higgins, C. F.; Ford, R. C. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J. Biol. Chem. 2003, 278, 8294-8299.
5. Chang, G.; Roth, C. Structure of MsbA from E. coli: a homologue of the multidrug resistance ATP binding cassette (ABC) transporters. Science 2001, 293, 1793-1800.
6. Seigneuret, M.; Garnier-Suillerot A. A structural model for the open conformation of the mdr1 P-glycoprotein based an the MsbA crystal structure. J. Biol. Chem. 2003, 278, 30115-30124.
7. Chang, G. Structure of MsbA from Vibrio cholera: A Multidrug Resistance ABC Transporter Homolog in a Closed Conformation. J. Mol. Biol. 2003, 330, 419-430.
8. Loo, T. W.; Clarke, D. M. Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine-scanning mutagenesis and thiol-modification techniques. Biochim. Biophys. Acta 1999, 1461, 315-325.
9. Loo, T. W.; Clarke, D. M. Determining the dimensions of the drug-binding domain of human P-glycoprotein using thiol crosslinking compounds as molecular rulers. J. Biol. Chem. 2001, 276, 36877-36880.
10. Loo, T. W.; Clarke, D. M. Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibrombimane. J. Biol. Chem. 2000, 275, 39272-39278.
11. Loo, T. W.; Clarke, D. M. Identification of residues in the drug-binding domain of human P-glycoprotein. J. Biol. Chem. 1999, 274, 35388-35392.
12. Loo, T. W.; Clarke, D. M. Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil, J. Biol. Chem. 2001, 276, 14972-14979.
13. Loo, T. W.; Clarke, D. M., Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding site. Proc. Natl. Acad. Sci. USA, 2002, 99, 3511-3516.
14. Loo, T. W.; Clarke, D. M. Location of the rhodamaine-binding site in the human multidrug resistance P-glycoprotein. J. Biol. Chem. 2002, 277, 44332-44338.
15. Loo, T. W.; Bartlett, M. C.; Clarke, D. M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. J. Biol. Chem. 2003, 278, 13603-13606.
16. Shapiro, A. B.; Ling, V. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specifities. Eur. J. Biochem. 1997, 250, 130-137.
17. Shapiro, A. B.; Fox, K.; Lam, P.; Ling, V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 1999, 259, 841-850.
18. Martin, C.; Berridge, G.; Higgins, C. F.; Mistry, P.; Charlton, P.; Callaghan, R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 2000, 58, 624-632.
19. Neuhoff, S.; Langguth, P.; Dressler, C.; Andersson, T. B.; Regardh, C. G.; Spahn-Langguth, H. Affinities at the verapamil binding site of MDR1-encoded- P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int. J. Clin. Pharmacol. Ther. 2000, 38, 168-79.
20. Wang, E.-J.; Casciano, C.; Clement, R. P.; Johnson, W. W. Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim. Biophys. Acta 2000, 1481, 63-74.
21. Kondratov, R. V.; Komarov, P. G.; Becker, Y.; Ewenson, A.; Gudkov, A. V. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc. Natl. Acad. Sci. USA, 2001, 98, 14078-14083.
22. Qu, Q.; Sharom, F. J. Proximity of bound hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmatic membrane leaflet. Biochemistry 2002, 41, 4744-4752.
23. Pajeva, I., Wiese, M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J. Med. Chem. 2002, 45, 5671-5686.
24. SWISS-PROT Release version 41.0, 2003 (www.ebi.ac.uk/swissprot)
25. Hunter, C. A., Singh, J., Thornton, J. M. Pi-pi interactions: the geometry and energetics of phenylalanine-phenylalanine interactions in proteins. J. Mol. Biol. 1991, 218, 837-846.
26. Mazeres, S.; Schram, V.; Tocanne, J. F.; Lopez, A. 7-nitrobenz-2-oxa-1,3-diszole-4-yl-labeled phospholipids in lipid membranes: differences in fluorescence behavior. Biophys. J. 1996, 71, 327-35.
27. Liu, R.; Sharom, F. J. Proximity of the nucleotide binding domains of the P-glycoprotein multidrug transporter to the membrane surface: a resonance energy transfer study. Biochemistry 1998, 37, 6503-12.
28. Seelig, J.; Gally, H. U.; Wohlgemuth, R. Orientation and flexibility of the choline headgroup in phosphatidylcholin bilayers. Biochim. Biophys. Acta 1977, 467, 109-119.
29. Stenham, D. R., Campbell, J. D., Sansom, M. S. P., Higgins, C. F., Kerr, I. D., Linton, K. J., An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulphide cross-linking and homology modelling. FASEB J. 2003, October 16, DOI fj.03-01071fje; FASEB J. 2003, 17, 2287-2289.
30. Stenham, D. R., Campbell, J. D., Sansom, M. S. P., Higgins, C. F., Kerr, I. D., Linton, K. J., An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulphide cross-linking and homology modelling. FASEB J. 2003, October 16, DOI fj.03-01071fje; FASEB J. 2003, 17, 2287-2289.
31. Sybyl, version 6.9; Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63114-2917; October 2002.
32. MOE 2002.03 (Molecular Operating Enviroment), Chemical Computing Group Inc., 1010 Sherbrooke Street West, Suite 910; Montreal, Quebec; Canada H3A 2R7MOE.
33. MOPAC 6, (QCPE No. 445): Department of Chemistry, Indiana University, Bloomington, IN 47405.
34. Lee, J. Y.; Urbatsch, I. L.; Senior, A. E.; Wilkens, S. Projection structure of P-glycoprotein by electron microscopy. Evidence for a closed conformation of the nucleotide binding domains. J. Biol. Chem. 2002, 277: 40125-40131.